Stay updated on ORACLE: Liquid Biopsy in Residual Cancer Clinical Trial
Sign up to get notified when there's something new on the ORACLE: Liquid Biopsy in Residual Cancer Clinical Trial page.

Latest updates to the ORACLE: Liquid Biopsy in Residual Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA notice announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence.” The site revision advances from v3.7.1 to v3.7.2, while the study record area still displays a 403 error.SummaryDifference1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe ClinicalTrials.gov footer revision label updates from v3.7.0 to v3.7.1, while the page remains a 403 Forbidden error page.SummaryDifference0.2%

- Check35 days agoChange DetectedThe study record page now displays a 403 Forbidden error, indicating access is blocked. The header and footer navigation remain visible on the error page, replacing the usual study content.SummaryDifference0.5%

- Check42 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the expected study record, with a simple header and a Home link. This indicates the page is currently inaccessible due to permission restrictions rather than new content changes.SummaryDifference21%

- Check49 days agoChange DetectedThe ORACLE study page was updated with new investigator and site information, expanded cohort and eligibility details, and revised enrollment numbers, along with a new Terminated status indicator. These updates reflect substantial changes to the study's scope and governance as displayed on the page.SummaryDifference2%

- Check63 days agoChange DetectedThe page's revision label was updated from v3.6.5 to v3.6.6. This signals a minor update to the page's release history.SummaryDifference0.0%

Stay in the know with updates to ORACLE: Liquid Biopsy in Residual Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ORACLE: Liquid Biopsy in Residual Cancer Clinical Trial page.